Berenberg Bank Reiterates €124.00 Price Target for Bayer (BAYN)
Bayer (FRA:BAYN) has been given a €124.00 ($147.62) price objective by analysts at Berenberg Bank in a research note issued to investors on Tuesday. The brokerage currently has a “neutral” rating on the healthcare company’s stock. Berenberg Bank’s price target points to a potential upside of 16.87% from the company’s current price.
A number of other equities analysts also recently commented on the company. J P Morgan Chase & Co restated a “buy” rating on shares of Bayer in a report on Wednesday, September 13th. Commerzbank set a €124.00 ($147.62) price target on Bayer and gave the stock a “buy” rating in a research note on Wednesday, November 15th. UBS set a €125.00 ($148.81) price target on Bayer and gave the stock a “buy” rating in a research note on Monday, November 6th. Goldman Sachs Group set a €125.00 ($148.81) price target on Bayer and gave the stock a “buy” rating in a research note on Tuesday, November 7th. Finally, Sanford C. Bernstein set a €126.00 ($150.00) price target on Bayer and gave the stock a “buy” rating in a research note on Tuesday, September 5th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of €122.43 ($145.75).
Bayer (FRA:BAYN) opened at €106.10 ($126.31) on Tuesday. Bayer has a twelve month low of €86.06 ($102.45) and a twelve month high of €123.82 ($147.40).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.